Reaffirmed: AzurRx BioPharma Inc (AZRX) Buy Rating Reconfirmed at H.C. Wainwright; $8.0 Target in Place

February 25, 2018 - By Adrian Erickson

 Reaffirmed: AzurRx BioPharma Inc (AZRX) Buy Rating Reconfirmed at H.C. Wainwright; $8.0 Target in Place

AzurRx BioPharma Inc (AZRX) Rating Reaffirmed

Stock analysts at H.C. Wainwright now has a $8.0 PT on AzurRx BioPharma Inc (AZRX). H.C. Wainwright and their recent PT would indicate a potential upside of 193.04 % from the company’s current price. The rating has been revealed to clients and investors in a research report on 17 November.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) Ratings Coverage

Among 2 analysts covering AzurRx BioPharma (AZRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AzurRx BioPharma has $8 highest and $7.0 lowest target. $7.50’s average target is 174.73% above currents $2.73 stock price. AzurRx BioPharma had 8 analyst reports since December 6, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 24 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 16 report. The firm has “Buy” rating by H.C. Wainwright given on Friday, November 17. WallachBeth Capital initiated the stock with “Buy” rating in Tuesday, December 6 report. The stock has “Buy” rating by H.C. Wainwright on Friday, January 19. H.C. Wainwright maintained the shares of AZRX in report on Thursday, September 28 with “Buy” rating. The firm earned “Buy” rating on Monday, October 23 by H.C. Wainwright.

The stock decreased 2.15% or $0.06 during the last trading session, reaching $2.73. About 66,921 shares traded or 32.63% up from the average. AzurRx BioPharma, Inc. (AZRX) has 0.00% since February 25, 2017 and is . It has underperformed by 16.70% the S&P500.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company has market cap of $31.54 million. The Company’s product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. It currently has negative earnings.

More notable recent AzurRx BioPharma, Inc. (NASDAQ:AZRX) news were published by: Globenewswire.com which released: “AzurRx BioPharma Announces Closing of $5.0 Million Private Financing” on June 08, 2017, also Globenewswire.com with their article: “AzurRx Announces Addition of Charles J Casamento to the Board of Directors” published on March 08, 2017, Globenewswire.com published: “AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference …” on February 08, 2018. More interesting news about AzurRx BioPharma, Inc. (NASDAQ:AZRX) were released by: Businesswire.com and their article: “AzurRx BioPharma Announces Pricing of Initial Public Offering” published on October 12, 2016 as well as Globenewswire.com‘s news article titled: “WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma” with publication date: December 12, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.